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Abstract
Background
Despite intensive surveillance, a high rate of interval malignancies is still seen in women at
increased breast cancer risk. Therefore, novel screening modalities aiming at early detec-
tion remain needed. The intraductal approach offers the possibility to directly sample fluid
containing cells, DNA and proteins from the mammary ductal system where, in the majority
of cases, breast cancer originates. Fluid from the breast can non-invasively be obtained by
oxytocin-assisted vacuum aspiration, called nipple fluid aspiration (NFA). The goal of this
feasibility study was to evaluate the potential of repeated NFA, which is a critical and essen-
tial step to evaluate its possible value as a breast cancer screening method.
Methods
In this multicenter, prospective study, we annually collected nipple fluid for up to 5 consecu-
tive years from women at increased breast cancer risk, and performed a questionnaire-
based survey regarding discomfort of the aspiration. Endpoints of the current interim analy-
ses were the feasibility and results of 994 NFA procedures in 451 women with total follow-
up of 560 person years of observation.
Results
In this large group of women at increased risk of breast cancer, repetitive NFA appeared to
be feasible and safe. In 66.4% of aspirated breasts, nipple fluid was successfully obtained.
Independent predictive factors for successful NFA were premenopausal status, spontane-
ous nipple discharge, smaller breast size, bilateral oophorectomy and previous use of
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hormone replacement therapy or anti-hormonal treatment. The procedure was well tolerat-
ed with low discomfort. Drop-out rate was 20%, which was mainly due to repeated unsuc-
cessful aspiration attempts. Only 1.6% of women prematurely declined further participation
because of side effects.
Conclusions
Repeated NFA in women at increased breast cancer risk is feasible and safe. Therefore,
NFA is a promising method to non-invasively obtain a valuable source of potential breast
cancer specific biomarkers.
Introduction
Breast cancer causes the highest cancer related mortality in women with 458,000 deaths world-
wide in 2008 [1]. Moreover, the incidence of breast cancer is high with a lifetime risk of approx-
imately 13% for a woman in The Netherlands. This risk increases dramatically in women
carrying a breast cancer susceptibility gene, such as TP53, PTEN, LKB1, CDH1, or, most fre-
quently, BRCA1 or BRCA2 [2]. Women carrying a germline BRCA1mutation have a 57–65%
chance of developing breast cancer before the age of 70 years, which for BRCA2mutation carri-
ers is 45–55% [3–5]. After having developed unilateral breast cancer, BRCA1/2mutation carri-
ers are also at increased risk of subsequent contralateral breast cancer. This risk is estimated to
be 20–60% or even higher and is influenced by various factors such as age at diagnosis and ad-
juvant systemic therapy [5,6].
To date, the most effective preventive options in women at increased breast cancer risk are
bilateral or contralateral prophylactic mastectomy (PM) and/or prophylactic bilateral sal-
pingo-oophorectomy (PBSO). PM yields a risk reducing effect of more than 95% in healthy
BRCA1/2mutation carriers [7]. PBSO before the age of 50 years decreases breast cancer risk in
BRCA1/2mutation carriers without prior breast cancer (HR 0.36–0.63) [8]. Data about the
breast cancer reducing effect of PBSO in postmenopausal women are conflicting [8,9]. An al-
ternative preventive strategy could be chemoprevention with anti-hormonal therapy, but evi-
dence of efficacy so far is marginal [10].
Another option to prevent breast cancer related mortality in high risk women is intensive
surveillance including e.g. mammography and MRI. In follow-up studies, annual MRI signifi-
cantly reduced the incidence of advanced-stage breast cancers in BRCA1/2 mutation carriers
[11] and detected the majority of breast cancers at an early and favorable stage [12]. MRI is
more sensitive but less specific than mammography in detecting invasive breast cancer. Strik-
ingly, the sensitivity of mammography in diagnosing breast cancer is lower in BRCA1mutation
carriers compared to BRCA2mutation carriers or women with a moderate to high familial
breast cancer risk [13]. Moreover, BRCA1mutation carriers have more interval cancers (32%)
and an unfavourable tumor size at diagnosis [13]. Other disadvantages of breast cancer screen-
ing are difficulties in interpreting imaging in women with dense breasts, false positive results
leading to additional examinations and higher costs, and more distress [14–16].
The intraductal approach offers a way to directly access or sample fluid from the mammary
ductal system, where in the majority of patients breast cancer develops. Nipple fluid contains
cells, DNA and proteins directly derived from the breast ducts and can thereby be a rich source
of breast cancer biomarkers [17,18]. Fluid from the breast can be obtained by invasive tech-
niques like random fine needle aspiration (FNA) or ductal lavage (DL), but nipple fluid can
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also be obtained in a completely non-invasive way by an oxytocin-assisted nipple fluid aspira-
tion (NFA) under vacuum. Besides being less invasive, NFA causes less discomfort and is easier
to perform compared to invasive techniques [19]. We have previously shown that, with this
technique, nipple fluid can be obtained successfully and without discomfort in healthy women
and women at increased risk of breast cancer [20,21].
In the present analyses, we investigated the feasibility of and variables affecting a successful
NFA procedure in a prospective, multicenter study where nipple fluid was obtained annually
in women at increased breast cancer risk adhering to a surveillance program. Also, compliance
and discomfort associated with the procedure was studied. The goal of this clinical feasibility
study was to evaluate the potential of repeated nipple fluid aspiration, which is a critical and es-
sential step to evaluate its possibility as a breast cancer screening method.
Methods
Study protocol and population
Women at increased risk of breast cancer adhering to a regular surveillance program were in-
cluded in this prospective clinical study aiming to establish methylation profiles in nipple fluid.
According to the Dutch guidelines, the surveillance program provides imaging based screening
as standard of care for women at increased breast cancer risk based on inheritance or a history
of breast cancer. The study design is observational: a cohort of high-risk women is being fol-
lowed from baseline to the end of follow-up or until development of breast cancer or (preven-
tive) breast surgery. Nipple fluid was aspirated annually, for a follow-up period of five years.
Besides ending the follow-up period of five years, participation could be discontinued because
of the development of breast cancer, breast surgery making NFA impossible, or the exclusion
of a BRCA1/2mutation after genetic testing. Person years of observation were calculated from
baseline to the last NFA procedure or last moment of contact with the participant.
Apart from the NFA, participants had their regular follow-up consultations with the physi-
cian or nurse practitioner and their imaging examinations. The indication for breast surgery
was based on usual clinical and radiological findings, and some patients opted for risk reducing
mastectomy at which time the follow-up into the study stopped. Physicians and patients re-
mained blinded to the results of the nipple aspirate analyses. Enrolment of participants started
at August 7, 2008 in the University Medical Center Utrecht (UMCU) and at April 22, 2011 in
the Erasmus Medical Center Rotterdam (EMC).
The study has been approved by the Ethics Committees of the UMCU and the EMC, The
Netherlands (ABR NL 11690.041.06, METC 06–091). Written informed consent was obtained
from all participants.
The objective of the present analysis was to assess the feasibility and compliance of repeated
NFA, the variables predictive for a successful aspiration of nipple fluid, and discomfort experi-
enced by participants in comparison with other surveillance procedures and breast feeding.
Study population
Women at increased risk of developing (a new) breast cancer adhering to a surveillance pro-
gram were eligible for the study, including: carriers of a BRCA1 or BRCA2 gene mutation,
women with a pedigree-based increased lifetime breast cancer risk, or a history of DCIS or in-
vasive breast cancer. Exclusion criteria were age below 18 years, bilateral mastectomy, pregnan-
cy or lactation, active breast infection, and disseminated breast cancer.
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Nipple fluid aspiration technique
The technique of NFA has been previously described [17,21]. In short, anaesthetic cream
(Emla) was applied onto the nipple, after which the breasts were warmed with hot pads.
Women were then administered oxytocin nasal spray into both nostrils (see below). A suction
cup (aspirator; one-day pump set manufactured by Medela; as from December 2012 one-day
pump set manufactured by Beldico because of supply issues) was placed over the nipple. Re-
peated, intermittent manual gentle suction with a 20 cc syringe connected to the suction cup
drew fluid to the nipple surface. If necessary, suction was applied for 20 to 30 minutes. Droplets
were collected by capillary tubes (Fig 1). The entire procedure was applied to each breast sepa-
rately. The collected fluid from different ducts of each breast was pooled and conserved in a
buffer solution (50mM Tris pH 8.0, 150mMNaCl, 2mM EDTA) at -80°C until analysis. The
procedure was called successful if droplets were visible on the surface of the nipple and could
be collected with the capillary tube.
To test the feasibility of obtaining nipple fluid with an electric pump, we also performed a
pilot study in 43 women in which vacuum was applied simultaneously to both breasts using an
electric device (Medela Symphony, Baar, Switzerland) for approximately 15–20 minutes. If
after 10 minutes no droplets were seen, a second dose of oxytocin was given and the aspiration
procedure was repeated.
Fig 1. Nipple fluid collected by a capillary tube after nipple fluid aspiration (NFA).
doi:10.1371/journal.pone.0127895.g001
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Oxytocin hormonal nasal spray
Participants received oxytocin nasal spray (Syntocinon) in a dose of 4 IU per spray in order to
stimulate the production of nipple fluid. One spray of nasal oxytocin contains 4 IU and is the
standard dose to induce lactation in breastfeeding women. In the mammary gland, oxytocin in-
duces contraction of the myoepithelial cells which surround the milk-storing alveoli and in this
way facilitates the release of milk from the breast during lactation [22]. Moreover, oxytocin
causes rhythmic contractions of the uterus during labour and has been shown to play a role in
the central nervous system regulating for example maternal, sexual and social behaviour [22].
Reported adverse events in the Summary of Product Characteristics of nasal oxytocin in-
clude headache (<1/1,000), nausea (<1/1,000), allergic dermatitis (<1/1,000), and uterine con-
tractions (<1/100). Syntocinon is quickly absorbed by the nasal mucosa and effective 5
minutes after administration. In case of supratherapeutic dosing, the oxytocin will be swal-
lowed and degraded quickly by proteolytic enzymes in the gastro-intestinal tract. Oxytocin has
a half-life that varies from 3 to 20 minutes and it is mainly eliminated by the liver and the kid-
neys [23].
Questionnaires
A questionnaire addressing age, phase in menstrual cycle, menarche, menopause, use of oral
anticonceptives or hormonal replacement therapy, parity, breast feeding, spontaneous nipple
discharge, prior mammography, prior palpable masses in the breast, biopsy or breast surgery,
oophorectomy and chemo- or radiotherapy, was filled out before the first NFA procedure, and
updated at every subsequent visit. Spontaneous nipple discharge is defined as physiologic dis-
charge which is spontaneous, usually bilateral, involves multiple ducts and does not contain
blood. Around 50%-80% of women in their reproductive years can express fluid from their
breasts. Spontaneous nipple discharge is different from pathological nipple discharge, which is
unilateral, and can be bloody, serous, clear, or associated with a mass [24]. A discomfort ques-
tionnaire was completed by the participant together with the research nurse after every NFA
procedure where discomfort was scored on a scale from zero (no discomfort) to ten (worst
imaginable discomfort). The discomfort questionnaire was based on the pain questionnaire for
the evaluation of NFA developed by Klein et al. [25]. In order to be able to put the experienced
discomfort during NFA into perspective, discomfort of other breast examination procedures
and breast feeding was asked and compared with the NFA procedure.
Statistical analyses
For statistical analyses IBM SPSS Statistics Version 20 was used. A two-sided P-value<0.05 was
considered statistically significant. To account for the clustered data, we analysed the nipple fluid
aspiration procedure results using repeated measurement analysis by General Estimation Equa-
tions (GEE) with participant as the subject level and breastvisit as within-subject levels, using ro-
bust standard error estimation and accounting for within-subject dependencies assuming an
autoregressive relationship. For categorical outcomes (aspect, volume, and number of drops of
nipple fluid) we used a cumulative logit multinomial approach, and for success rate a negative bi-
nomial approach with a log link (providing accurate relative risk estimates for determinants in
view of the high overall success rate). The reported overall frequency of the various outcomes
and the frequency of success in patient subgroups are based on the GEE-estimated values. We
used a stepwise-backward multivariable selection approach for determinants of aspiration suc-
cess (through P<0.1). To compare electric and manual aspiration, we made use of paired analy-
ses from the electric aspiration compared with a manual aspiration the visit before, or after if
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there was no earlier visit. Cases were excluded if only one visit with electronic aspiration was per-
formed. To analyse discomfort rates, only the first visit was taken into account.
Results
Baseline characteristics of participants
At the time of analysis, a total of 994 NFA procedures had been performed in 451 women
(UMCU: 292, EMC: 159). Since the Erasmus Medical Center started including participants
from April 2011, only first and second year participants of this center were yet analysed. 295
women underwent a second NFA, 139 a third, and 84 a fourth. A total of 25 women completed
the follow-up period of 5 years and 88% of them were willing to continue follow-up. Taken to-
gether there were 560 person years of observation at time of analysis.
Baseline characteristics and reasons for inclusion of participants are shown in Table 1.
Mean age at inclusion was 47.9 years (median 48.0 years) with a range of 21 to 79 years.
Characteristics of obtained nipple fluid
The aspect of the obtained fluid was clear in 56.0%, cloudy in 31.0%, different colours from sev-
eral ducts in 12.7%, and bloody in 0.3%. The estimated volume of the fluid aspirated was less
than 5 μl in 37.1%, 5–50 μl in 59.6%, and more than 50 μl in 3.3% of women. In 74.8% of
women 1 or 2 droplets were aspirated, in 21.2% 3 or 4 droplets, and in 4.0% 5 droplets or more.
Success rates of nipple fluid aspiration
To analyse the influence of clinical characteristics on successful aspiration, analyses were done
considering NFA per breast taking into account within-participant dependency between obser-
vations from each breast. NFA was performed in 1824 breasts and aspiration was successful in
66.4%. Table 2 shows the relation between baseline characteristics and success of NFA. Age,
history of spontaneous nipple discharge, breast size, menopausal status, and current use of oral
contraceptives were significantly correlated with success rate of NFA in univariate analysis.
Using multivariate analysis postmenopausal status (RR = 0.74, CI95% 0.65–0.84), smaller
breast size (RR = 1.11, CI95% 1.01–1.22), history of spontaneous nipple discharge (RR = 1.23,
CI95% 1.11–1.36), bilateral oophorectomy (RR = 1.16, CI95% 1.01–1.34), and a history of hor-
mone replacement therapy (RR = 1.27, CI95% 1.08–1.49) or anti-hormonal treatment
(RR = 1.21, CI95% 1.04–1.42) independently predicted the success rate of NFA (Table 2).
In the 43 participants from whom nipple fluid was obtained with an electric breast pump,
the procedure was successful in 62.3%. The success of obtaining fluid did not significantly differ
between the manual or electric procedure in the same participant (P = 0.115), and the proce-
dure takes on average 15 minutes less than manual aspiration.
Discomfort and side effects of nipple fluid aspiration
Fig 2A shows the discomfort scores of NFA and other procedures related to breast cancer care.
The total discomfort of the entire NFA procedure in 451 aspirations during the first visit was
on average rated at 0.71 (CI95% 0.64–0.78). This was significantly lower (all P-values<0.001;
see also Fig 2A) than discomfort experienced during breast feeding (mean 2.51), physical breast
examination (mean 1.15), mammography (mean 5.17), and MRI of the breasts (mean 3.55).
Discomfort of the electric NFA was rated at 0.63, which did not significantly differ from the
manual procedure in paired analyses of women undergoing both manual and electric NFA
(P = 0.312). In Fig 2B discomfort scores of the different parts of the NFA procedure are shown.
The application of vacuum was the most uncomfortable part of the procedure.
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Table 1. Baseline characteristics of 451 women at increased breast cancer risk undergoing (repeated) NFA.
Characteristic Subgroups N %
Total 451 100
Age (years) <40 107 23.7
40–49 137 30.4
50 207 45.9
Genetic status No genetic examination performed 215 47.7
No susceptibility factor detected 124 27.5
BRCA1 mutation 61 13.5
BRCA2 mutation 35 7.8
Unclassiﬁed variant BRCA 1 0.2
BRCA1/2 in family 12 2.7
CDH1 3 0.7
Lifetime breast cancer risk based on genetic status and family history¶ Standard* 125 27.7
Moderate 60 13.3
High 26 5.8
Very high 113 25.1
Unknown 127 28.2
Personal history of breast cancer None 283 62.7
DCIS 30 6.7
Invasive carcinoma 138 30.6
History spontaneous nipple discharge Yes 74 16.4
No 377 83.6
Number of live births 0 115 25.5
1–2 264 58.5
3 72 16.0
Age at ﬁrst birth (years) <25 91 20.2
25–29 132 29.3
30 113 25.1
Not applicable (nulliparous) 115 25.5
Previous breast feeding Yes 268 59.4
No 183 40.6
Age at menarche (years) <12 138 30.6
12–14 152 33.7
14 156 34.6
Unknown 5 1.1
Menopausal status Premenopausal 209 46.3
Postmenopausal 241 53.4
Unknown 1 0.2
Age at menopause (years) <45 82 18.2
45–49 74 16.4
50 85 18.8
Not applicable (premenopausal) 209 46.3
Unknown 1 0.2
Current oral contraceptive use Yes 53 11.8
No 398 88.2
History oral contraceptive use Yes 416 92.2
No 33 7.3
Unknown 2 0.4
(Continued)
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In Table 3 all reported side effects are listed. In 2.2% of the NFA procedures an adverse
event was reported being potentially related to the procedure. All adverse events were mild and
self-limiting. 99.5% of participants confirmed to be willing to repeat NFA and 97.3% would
recommend the procedure to other women.
Follow-up of participants
During follow-up, 141 women (31.3%) left the study (Table 4), either because women declined
further participation (true drop-out) or follow-up ended if the follow-up period of 5 years was
completed (5.5%), genetic testing did not show a BRCA1/2mutation (0.7%), women under-
went preventive mastectomy (2.7%), or breast cancer developed. Twelve women developed
breast cancer during follow up (2.7%) and three women died from disseminated breast cancer
Table 1. (Continued)
Characteristic Subgroups N %
Total 451 100
Current intrauterine device Yes 20 4.4
No 427 94.7
Unknown 4 0.9
Current hormonal replacement therapy Yes 10 2.2
No 440 97.6
Unknown 1 0.2
History hormonal replacement therapy Yes 33 7.3
No 414 91.8
Unknown 4 0.9
Breast size A-B 110 24.4
C-D 283 62.7
>D 53 11.8
Unknown 5 1.1
Oophorectomy in history Bilateral 95 21.1
Unilateral 6 1.3
No 350 77.6
Chemotherapy in history Yes 88 19.5
No 363 80.5
Radiotherapy in history Yes 131 29.0
No 320 71.0
Current anti-hormonal therapy Yes 48 10.6
No 397 88.0
Unknown 6 1.3
History anti-hormonal therapy Yes 62 13.7
No 389 86.3
Breast surgery in history Excision biopsy 30 6.6
Breast conserving surgery 116 25.7
Mastectomy 60 13.3
Other 33 7.3
¶ Lifetime breast cancer risk was based on the Dutch guidelines for hereditary cancers as published by STOET (Stichting Opsporing Erfelijke Tumoren)
and Vereniging Klinische Genetica Nederland in 2010 (http://stoet.nl/uploads/richtlijnenboekje.pdf)
* This group consists of women with a personal history of breast cancer
doi:10.1371/journal.pone.0127895.t001
Nipple Fluid Aspiration
PLOS ONE | DOI:10.1371/journal.pone.0127895 May 22, 2015 8 / 15
Table 2. Predictive factors for successful NFA per 1824 attempts per breast using repeatedmeasurement analysis.
Factor Subgroup Successful
aspiration
N Univariate
analysis
Multivariate
analysis
% P-value P-value
Age (years) <50 70.9 928
50 61.3 896 0.002* NS
BRCA1/2 mutation Yes 66.9 315
No 66.3 1509 0.893 NS
Breast cancer risk based on genetic status and family
history
Not
increased
63.0 400
Increased 67.3 1424 0.191 NS
DCIS/breast cancer in history Yes 62.2 662
No 68.6 1162 0.067 NS
Spontaneous nipple discharge Yes 76.3 342
No 64.3 1482 0.001* <0.001§
Breast size A-B 72.8 394
C 64.6 1419 0.015* 0.039§
Parity Nulliparous 66.5 497
Parous 66.4 1327 0.980 NS
Previous breast feeding Yes 67.1 1056
No 65.4 768 0.616 NS
Duration of lactation (months) 6 68.0 530
>6 65.6 528 0.582 NS
Menstrual cycle day 1–14 72.9 322
14 73.9 365 0.780 NS
Age at menarche (years) 13 65.5 1158
>13 67.7 663 0.505 NS
Postmenopausal Yes 61.0 1004
No 72.7 812 <0.001* <0.001§
Current oral contraceptive use Yes 75.3 247
No 65.1 1577 0.028* NS
History oral contraceptive use Yes 66.5 1652
No 64.1 168 0.671 NS
Intrauterine device Yes 68.0 88
No 66.3 1728 0.801 NS
Current hormonal replacement therapy Yes 77.8 42
No 66.1 1779 0.131 NS
History hormonal replacement therapy Yes 75.8 129
No 65.6 1687 0.053 0.005§
Previous chemotherapy Yes 63.4 293
No 67.0 1531 0.398 NS
Previous radiotherapy locally Yes 61.0 257
No 67.2 1557 0.171 NS
Current anti-hormonal therapy Yes 64.6 148
No 66.6 1667 0.678 NS
Previous anti-hormonal therapy Yes 67.7 237
No 66.3 1586 0.746 0.014§
Previous breast surgery¶ Yes 61.6 415
No 67.7 1409 0.114 NS
(Continued)
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that developed during follow-up (0.7%). True drop-out was 20.0% and mainly caused by re-
peated unsuccessful aspiration attempts (10.9%), or adverse events (1.6%).
Discussion
In this multicenter, prospective study, we annually collected nipple fluid for up to 5 consecutive
years from women at increased breast cancer risk adhering to a surveillance program. We were
able to obtain nipple fluid by vacuum aspiration and using oxytocin nasal spray in 66.4% of as-
pirated breasts. Annually repeated aspiration was feasible and very well tolerated with the
occurrence of very few and self-limiting adverse events. Success rates were higher in premeno-
pausal women, in women with a history of spontaneous nipple discharge, bilateral oophorecto-
my, previous hormonal replacement therapy or anti-hormonal therapy, and in women with
smaller breast size. True drop-out was mainly due to repetitively unsuccessful aspiration.
Table 2. (Continued)
Factor Subgroup Successful
aspiration
N Univariate
analysis
Multivariate
analysis
% P-value P-value
Bilateral oophorectomy Yes 64.9 355
No 67.9 1468 0.713 0.038§
¶ Including excision, breast conserving surgery, breast augmentation, breast reducing surgery
* Statistically signiﬁcant predictor in univariate analysis
§ Statistically signiﬁcant predictor in stepwise-backward multivariable analysis
doi:10.1371/journal.pone.0127895.t002
Fig 2. A, Discomfort of NFA compared to other breast cancer screening procedures (mean with 95% confidence intervals). B, Discomfort of different
procedures during NFA (mean with 95% confidence intervals).
doi:10.1371/journal.pone.0127895.g002
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Our first experience with NFA was obtained in healthy volunteers, where aspiration was
successful in 94% of patients and in 84% per breast. Having spontaneous nipple discharge
showed to be the only predictive factor in successfully obtaining nipple fluid. The procedure
was well tolerated and no side effects from using oxytocin nasal spray were reported [20]. After
this feasibility study, we started the prospective collection of nipple fluid in women at increased
risk of breast cancer, our target population for introducing a potential new screening method.
Preliminary results showed that NFA was also possible in this group of women [21]. In the
Table 3. Adverse events reported during and after 994 NFA procedures.
Adverse event N %
Side effects probably related to NAF procedure
Sensitive breasts 7 0.7
Local irritation nipple or surrounding skin 4 0.4
Spontaneous nipple discharge after NFA 1 0.1
Cramps in uterus / abdominal discomfort 5 0.5
Total 17 1.7
Side effects possibly related to NAF procedure
Nausea 2 0.2
Headache 1 0.1
Insomnia night after NFA procedure 2 0.2
Total 5 0.5
doi:10.1371/journal.pone.0127895.t003
Table 4. Reasons for leaving the study of repeated NFA in 451 women at increased breast cancer risk.
Reason N %
End of study
Completed follow-up period of 5 years 25 5.5
Breast cancer diagnosis during follow up¶ 11 2.4
Preventive bilateral mastectomy during follow-up 11 2.4
No BRCA1/2 mutation identiﬁed at genetic testing 3 0.7
Reductive mammoplasty including nipple reduction during follow-up 1 0.2
Total 51 11.3
Drop-out
Repeated unsuccessful aspiration 49 10.9
Adverse events due to NFA procedure 7 1.6
- Vaginal candida* 1
- Pain around nipple 4
- Gorges around nipple 1
- Sensitive breasts 1
Too high burden of nipple ﬂuid procedure because of general health 7 1.6
Lack of time 4 0.9
Afraid of recurrent nipple discharge 1 0.2
Other reason 22 4.9
Total 90 20.0
¶ One of the women that developed breast cancer during follow-up continued participating in the study.
* Developing vaginal candida after NFA is unlikely to be related to the procedure, however it was the
reason to end the study for this participant
doi:10.1371/journal.pone.0127895.t004
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present follow-up study, we show for the first time in a large group of high-risk women that re-
petitive NFA is a feasible and safe method. We could obtain nipple fluid in a clearly higher per-
centage compared to earlier studies in high risk women [26–28]. However, success rates were
lower than observed in our earlier feasibility study in healthy volunteers [20]. The group of
healthy volunteers consisted of younger women with a mean age of 29 years and only 12% of
included women were postmenopausal, compared to 53% postmenopausal women in the pres-
ent study. This difference may explain the higher success rates in our previous group of
healthy volunteers.
In order to optimize adherence to nipple fluid aspiration as a new screening tool, we tested
the feasibility of an electric breast pump, allowing women to obtain nipple fluid at home, in a
subgroup of women. As the success rate was comparable to manual aspiration, we are currently
optimizing the procedure for at home use, which may facilitate using NFA in a wider screening
setting.
Other publications on obtaining breast fluid in high-risk women focused mainly on ductal
lavage. In these studies NFA is solely used to identify fluid yielding ducts which can be cannu-
lated by ductal lavage. Higgins et al. reported that fluid yielding ducts could be identified in
36% of high risk women (N = 33), in contrast to in 84% of women without an increased risk.
Reduced yield of nipple fluid was associated with postmenopausal state, BRCA germline muta-
tion and a history of risk reducing strategies such as PBSO or use of selective estrogen receptor
modulator inhibitors. The authors hypothesized that endocrine mechanisms associated with
risk-reducing therapies could explain the diminished production of nipple fluid [26]. Mitchell
et al. identified fluid yielding ducts in 60% of BRCAmutation carriers (N = 52) and again post-
menopausal status was associated with less fluid yielding [27]. Twelves et al. also studied
women at increased breast cancer risk (N = 67), but did not include women with a known
BRCAmutation. Nipple fluid was produced in 83% in at least one duct. Following NFA, 77% of
ducts were cannulated for ductal lavage of which 83% produced samples with adequate cellu-
larity. In 40% women experienced mild discomfort after ductal lavage. One women developed
mild breast inflammation, resolving after antibiotics. Total drop-out rate was 21%. Withdrawal
occurred in 3 women because of intolerance of the procedure and in another 3 by anxiety and
pain [28]. These studies show that breast fluid can be obtained in high risk women, but success
rates vary. Moreover, discomfort of ductal lavage is considerably higher than we experienced
after our non-invasive nipple fluid aspiration.
An important difference between the present and earlier studies is the use of oxytocin nasal
spray, which may explain higher success rates. Oxytocin is a hormone which plays a key role in
the contraction of the uterus during parturition. Moreover, oxytocin is important in the ejec-
tion of milk from the mammary gland during breast feeding. In the present study the incidence
of reported side effects was low. In 1.7% side effects were probably related to the aspiration pro-
cedure and in 0.5% possibly. The adverse events were mild and self-limiting in all cases. Ab-
dominal discomfort was reported in 0.5% of aspirations after the procedure, which could be
specifically related to the use of oxytocin. Long-term effects were not observed, which is in ac-
cordance with the findings of the use of long-term oxytocin intranasally in male children with
autism (8–24 IU/dose) [29]. In the study by Zhang et al., 9 healthy women were given one
spray of oxytocin in both nostrils (total dose 50 IU) before NFA and no adverse events were re-
ported [30]. This makes the use of oxytocin safe and helpful in obtaining nipple fluid.
A limitation of NFA applicability in screening programs is that, at this point, fluid can be ob-
tained in 66% of the breasts aspirated. To increase nipple fluid yielding, it is important to get
more insight into the determinants affecting successful aspiration. It has been shown that the
yielding of nipple fluid is associated with higher prolactin, regardless of parity and menopausal
status [31]. Together with our and other findings that NFA is more successful in premenopausal
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women, this implies that endocrine environment is important in nipple fluid yielding. Another
important note is that we only performed one nipple fluid aspiration attempt per participation
year. Studies describing multiple attempts in women with both standard and increased breast
cancer risk, report a 94% or higher success rate in obtaining nipple fluid [32]. This implies that
multiple aspirations might increase successful nipple aspirations and this further increases the
necessity for self-testing at home.
Nipple fluid contains cells and free DNA, which makes it suitable for the detection of differ-
ent biomarkers such as methylation [33–37], proteins [38], and hormones [39]. Although low
nipple volumes may hamper a multidisciplinary biomarker approach, we believe much of its
limitations can be overcome due to the continuous development of increasingly sensitive tech-
niques, and all-in-one DNA/RNA/protein isolation methods. Besides, we have already demon-
strated that methylation analysis in nipple fluid samples from high risk women is feasible [21].
At this moment we are analysing the nipple fluid samples to investigate if the process of breast
carcinogenesis can be predicted by the occurrence of methylation aberrations. Moreover, we
collected nipple fluid samples from healthy volunteers and breast cancer patients for compari-
son. Results from nipple fluid analyses will be reported in a separate paper.
In conclusion, sampling of nipple fluid as breast-derived material with oxytocin-assisted as-
piration is a feasible and promising approach yielding a valuable source of breast cancer specif-
ic biomarkers. Since sampling of nipple fluid is feasible in a screening population, the samples
could be used for many different purposes like methylation, protein, or hormone biomarkers
analysis.
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